Dutta Pinaki, Bhansali Anil, Masoodi Shriq Rashid, Bhadada Sanjay, Sharma Navneet, Rajput Rajesh
Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh-160012, India.
Crit Care. 2008;12(1):R1. doi: 10.1186/cc6211. Epub 2008 Jan 3.
With the easy availability of thyroid hormone assays, thyroid disorders are now recognised even in a subclinical state. However, patients are still seen with advanced manifestations of the disease, particularly in developing countries. This observational study analysed the predictors of outcome in patients with myxoedema coma and tested the validity of different modules to define morbidity and mortality in these patients.
Twenty-three consecutive patients with myxoedema coma who presented from January 1999 to August 2006 were studied. The thyroid function test and random serum cortisol were measured in all patients at the time of admission. Patients were given oral or intravenous (i.v.) thyroxine with intention to treat with the latter according to availability. Various modules that predict outcome, including Glasgow Coma Scale (GCS), Acute Physiology and Chronic Health Evaluation II (APACHE II) score, and Sequential Organ Failure Assessment (SOFA) score, were analysed. SOFA score was repeated every 2 days until the time of discharge or demise.
Twenty-three patients (20 women; 87%) of 59.5 +/- 14.4 years of age (range, 30 to 89 years) were seen during the study period. Nine (39%) patients were diagnosed with hypothyroidism for the first time at the time of presentation of myxoedema coma, whereas 14 (70%) were diagnosed with hypothyroidism previously. However, the treatment defaulters presented early to the hospital and had more severe manifestations than de novo subjects. Nineteen (82%) had thyroprivic (primary) and 4 (17%) had trophoprivic (secondary) hypothyroidism. Fifteen (65%) patients presented in the winter and in 17 (74%) sepsis was the major accompanying comorbidity. Twelve (52%) had a history of diuretic use, thereby delaying the initial diagnosis. Patients who received oral L-thyroxine had no difference in outcome from those receiving i.v. thyroxine. Twelve (52%) subjects died and sepsis was the predominant cause of death. Various predictors of mortality included hypotension (p = 0.01) and bradycardia (p = 0.03) at presentation, need for mechanical ventilation (p = 0.00), hypothermia unresponsive to treatment (p = 0.01), sepsis (p = 0.01), intake of sedative drugs (p = 0.02), lower GCS (p = 0.03), high APACHE II score (p = 0.04), and high SOFA score (p = 0.00). However, SOFA score was more effective than other predictive models as baseline and day 3 SOFA scores of more than 6 were highly predictive of poor outcome.
L-Thyroxine treatment defaulters had more severe manifestations compared with de novo subjects. Outcome was not influenced by either aetiology or route of administration of L-thyroxine, and SOFA score was the best outcome predictor model.
随着甲状腺激素检测方法的普及,甲状腺疾病如今即便在亚临床状态下也能被识别出来。然而,仍有患者出现该疾病的晚期表现,尤其在发展中国家。这项观察性研究分析了黏液性水肿昏迷患者预后的预测因素,并测试了不同模块在定义这些患者发病率和死亡率方面的有效性。
对1999年1月至2006年8月期间连续收治的23例黏液性水肿昏迷患者进行研究。所有患者入院时均进行甲状腺功能检查及随机血清皮质醇检测。根据可获得性,给予患者口服或静脉注射甲状腺素,优先选择静脉注射。分析了包括格拉斯哥昏迷量表(GCS)、急性生理与慢性健康状况评价II(APACHE II)评分及序贯器官衰竭评估(SOFA)评分等多种预测预后的模块。每2天重复一次SOFA评分,直至出院或死亡。
研究期间共收治23例患者(20例女性,占87%),年龄59.5±14.4岁(范围30至89岁)。9例(39%)患者在黏液性水肿昏迷发作时首次被诊断为甲状腺功能减退,而14例(70%)此前已被诊断为甲状腺功能减退。然而,未规律治疗的患者更早入院,且表现比初发患者更严重。19例(82%)为甲状腺激素缺乏性(原发性),4例(17%)为促甲状腺激素缺乏性(继发性)甲状腺功能减退。15例(65%)患者在冬季发病,17例(74%)伴有败血症这一主要合并症。12例(52%)有使用利尿剂史,从而延误了初始诊断。接受口服左甲状腺素的患者与接受静脉注射甲状腺素的患者在预后方面无差异。12例(52%)患者死亡,败血症是主要死因。多种死亡预测因素包括入院时低血压(p = 0.01)、心动过缓(p = 0.03)、需要机械通气(p = 0.00)、治疗无效的体温过低(p = 0.01)、败血症(p = 0.01)、使用镇静药物(p = 0.02)、较低的GCS评分(p = 0.03)、较高的APACHE II评分(p = 0.04)及较高的SOFA评分(p = 0.00)。然而,SOFA评分比其他预测模型更有效,因为基线及第3天SOFA评分超过6分高度提示预后不良。
与初发患者相比,未规律接受左甲状腺素治疗的患者表现更严重。左甲状腺素的病因及给药途径均不影响预后,SOFA评分是最佳的预后预测模型。